TEVA logo

TEVA PHARMACEUTICAL IND LTD

TEVANYSE
US Equity
$39.97β–² $1.16 (+2.90%)
Live
πŸ””
Track TEVA
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 2.9%
7dβ–² 1.2%
14dβ–² 2.0%
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$46.54B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
+4.1%
Slowing
πŸ“ŠGross Margin
52.9%
Healthy
πŸ’΅FCF Margin
9.0%
Moderate
βš–οΈP/S Ratio
2.6x
Cheap
Otter Score
72
Fair

Trading Snapshot

Day Range
$39.49 – $40.62
52-Week Range
$6,160.00 – $12,150.00
Volume
$3.48B
Avg Volume
$3.45B
Shares Outstanding
1.16B
Next Earnings
Dec 8, 2026

Fundamentals Snapshot

Annual Revenue
$17.26B
Last Q Revenue
$4.14B
P/E Ratio
64.5
P/S Ratio
2.6x
EPS (TTM)
$0.60
Dividend Yield
β€”
Dilution (1yr)
+3.5%

Why Investors Own TEVA

  • βœ“High-growth profile β€” revenue up +34.2% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 36% gross margin and 18% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

TEVA logo

TEVA PHARMACEUTICAL IND LTD

TEVA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$17.3Bβ–² +4.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
51.8%β–² +6.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$2.2Bβ–Ό βˆ’811.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$1.1Bβ–² +53.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.17Bβ–² +3.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$13.8Bβ–² +$953M YoY
StockOtter Β· stockotter.space

About TEVA PHARMACEUTICAL IND LTD

Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
72/100

Analyst Price Target

β“˜
Average Target
$38.67
β–Ό βˆ’3.2% Downside
High Target$45.29
Low Target$35.47
Based on 27 analysts

Latest News & Updates